Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Inclusion Criteria

• •Understand and voluntarily sign an informed consent form
• •Able to adhere to the study visit schedule and other protocol requirements
• •Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy
• •Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug
• •Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.